Fecal calprotectin testing has emerged as a reliable non-invasive tool for diagnosing and monitoring inflammatory bowel diseases like Crohn's disease and ulcerative colitis. Fecal calprotectin is a protein released from the immune cells in the intestinal tract during inflammatory conditions. Calprotectin levels in the stool help determine the presence, severity, and extent of inflammation. Advantages of fecal calprotectin testing over other diagnostic tests include ease of sample collection via stool samples and high accuracy.
The global Fecal Calprotectin Test Market is estimated to be valued at US$ 140.6 M in 2024 and is expected to exhibit a CAGR Of 3.9% over the forecast period 2023 To 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The increased popularity of fecal calprotectin testing among physicians and patients can be attributed to its non-invasive nature compared to endoscopies or colonoscopies. Fecal calprotectin tests allow monitoring disease activity and response to therapy without invasive procedures. This reduces pain, risk of complications, and healthcare costs associated with alternative tests. The convenience and advantages of fecal calprotectin tests over other diagnostic modalities are expected to further boost the demand and push market revenue growth over the forecast period. Continuous technological advancements are also expected to aid the market growth through improved test kits, novel biomarkers and point-of-care devices.
Segment Analysis
The global fecal calprotectin test market is dominated by the immunoassay kits segment. This is because immunoassay kits are considered the gold standard for calprotectin testing and provide accurate quantitative results. Immunoassay kits utilize antibodies against calprotectin and make use of techniques like enzyme-linked immunosorbent assay (ELISA) for detection. They are widely adopted by diagnostic laboratories and hospitals due to their reproducibility and precision.
Key Takeaways
The Global Fecal Calprotectin Test Market Demand is expected to witness high growth over the forecast period of 2023 to 2030. The market is projected to expand at a CAGR of 3.9% during this period and reach a size of US$ 140.6 million by 2024.
Regional analysis
Europe currently dominates the global market and is expected to continue its dominance through 2030. This is due to the increased adoption of calprotectin testing across the European countries for diagnosis of intestinal inflammation. The region has a high awareness regarding gastrointestinal disorders and presence of advanced healthcare facilities. Asia Pacific is projected to witness the fastest growth over the coming years driven by developing economies like India and China. Rising incidence inflammatory bowel diseases and expanding medical infrastructure is fueling market growth in Asia Pacific.
Key players
Key players operating in the fecal calprotectin test market are BÜHLMANN Laboratories AG, Alpco, Kent Laboratories, Inc., Immundiagnostik AG, DiaSorin S.p.A., and others. BÜHLMANN Laboratories AG leads the market with its broad range of immunoassay kits for fecal calprotectin quantification. Other major players are focusing on new product launches, marketing & distribution partnerships to strengthen their position in the market.
Get more insights on this topic :
